Welcome to Action Kidney Cancer

The United Kingdom’s only patient-led kidney cancer charity

Patient Support Forum

Stronger together

In our own words

During this series of videos, kidney cancer patients and carers talk frankly about their experiences, emotions and how to live well with a diagnosis of kidney cancer
Coping with a diagnosis of kidney cancer
Talking about kidney cancer
A carer’s perspective

Real stories

The lives of all these people have been affected by kidney cancer
Some are patients, some are carers, all are stories by real people sharing their experiences of living with kidney cancer

Latest kidney cancer news

22 Jan 2025

Belzutifan plus cabozantinib combination shows promise in advanced kidney cancer

20 Jan 2025

Promising new combination therapy for advanced kidney cancer

9 Jan 2025

NHS England's Elective Care Reform Plan

8 Jan 2025

FDA approves injectable form of nivolumab

6 Jan 2025

NHS Help Us, Help You campaign

20 Dec 2024

NHS National Cancer Patient Experience Survey

9 Dec 2024

Promising new immunotherapy combination for advanced kidney cancer

5 Dec 2024

New treatment for pretreated advanced kidney cancer shows promise

18 Nov 2024

Cancer waiting times - latest updates

15 Nov 2024

The Big Cancer52 Conversation

12 Nov 2024

How to manage side effects to cabozantinib and nivolumab

1 Nov 2024

Government commits to a 'stand-alone cancer strategy'

Action Kidney Cancer

Friendship...community...encouragement...advocacy...information...support...kindness...advice...shared experiences...patient stories...research news...expert insights...empowerment...
Action Kidney Cancer
Action Kidney Cancer2 hours ago
With Valentines Day just around the corner, is there someone in your life you would like to show your appreciation to?

Our glass hearts are a great way to do this, any time of the year.

It could not be easier, email karen@actionkidneycancer.org with the number of hearts you would like, your chosen words from thank you, support, kindness and friendship.

Also provide Karen with the addresses you want them posted to with any personal message you would like added and we will do the rest.

The suggested minimum donation for each heart is £5.00 this includes the postage and packaging.

The money raised from this campaign will help us to continue supporting families affected by kidney cancer.

Thank you for your support. We are Stronger Together!

To donate please follow the link below:
https://www.justgiving.com/campaign/giftaheart

#giftaheart #kidneycancer #StrongerTogether
Action Kidney Cancer
Action Kidney Cancer1 day ago
Some exciting results from the phase 2 LITESPARK-003 trial with belzutifan and cabozantinib have been published recently. The study showed that the combination of belzutifan and cabozantinib had promising anti-cancer activity with manageable side effects in patients with advanced clear cell kidney cancer who had not previously been treated.

Read more on our website here:
Action Kidney Cancer
Action Kidney Cancer3 days ago
An interesting observational study, called MITRE, is looking for patients from 14 locations across the UK. The purpose of this study is to collect real world information on how the gut microbiome matches up with the safety and effectiveness of immunotherapies for patients with advanced kidney cancer, melanoma and non-small cell lung cancer.

The gut microbiome of a healthy person is made of many thousands of different bacteria. The types of bacteria in a person's microbiome can change over time and this can be influenced by things such as diet, drugs, genetics and infection. These bacteria play a central role in the digestion of food, development and regulation of our immune system, as well as our resistance to bacteria and viruses causing disease. Recent evidence suggest that the types of bacteria in a patient's gut microbiome plays a critical role in both the effectiveness and side effects of immunotherapy.

The aim of this study is to assess the microbiome of patients who are on immunotherapy, and link this to response to treatment. The researchers hope this work will help personalise treatment with immunotherapies based on the patient's microbiome. Also, researchers hope to be able change the types of bacteria in a patient's microbiome to make the best of their cancer immunotherapy treatment.

If you are interested in taking part in this study, please visit our clinical trial database for more information here:
Action Kidney Cancer
Action Kidney Cancer3 days ago
A recent early phase study in Chinese patients with advanced kidney cancer looked at the anti-cancer effectiveness and safety of a new combination of fruquintinib (a tyrosine kinase inhibitor that works by blocking the growth of new blood vessels in tumours) plus sintilimab (an immunotherapy that releases the ‘brakes’ on the immune system enabling T cells to attack and kill cancer cells more effectively) in treating advanced clear cell kidney cancer.

Read more on our website here:
Action Kidney Cancer
Action Kidney Cancer6 days ago
We have added a new video to the Ask the expert section of our website, many patients have asked 'What is the difference between kidney cancer and kidney disease?' In the new video we answer this question.

In this video interview, Steven Pointon talks with Dr Steve Bromage, Consultant Urological Surgeon, Stepping Hill Hospital, about the difference between kidney disease and kidney cancer, what happens to kidney function when a kidney is removed, monitoring kidney function, and how to manage kidney disease.

To watch the full video please follow the link below:

#single/0" target="_blank" rel="noreferrer">https://actionkidneycancer.org/help-support/ask-the-expert/#single/0

#kidneycancer #bypatientsforpatients #StrongerTogether
Action Kidney Cancer
'); jQuery( ".feed_dynamic_video_classeimbrnhwyy_page.fts-greater-than-width-height.fts-fb-video-on-page, .feed_dynamic_video_classeimbrnhwyy_page iframe" ).css({"height": "405px", "width": "720px"}); } }); });
Action Kidney Cancer
Action Kidney Cancer1 week ago
A clinical trial of a new cancer vaccine has opened at 5 sites in the UK.

This study investigates the effectiveness and safety of a combination of V940 injection (a cancer vaccine) plus a pembrolizumab infusion (an immunotherapy) compared to pembrolizumab plus placebo as an adjuvant treatment for patients who have had surgery to remove their cancer. An adjuvant treatment is a medication that is given after surgery to kill cancer cells that remain after surgery.

The study is for people who have a type of kidney cancer called clear cell renal cell carcinoma (RCC) or papillary RCC, which is at moderate or high risk of returning. It is also for people whose cancer has started to spread into surrounding tissue or to other parts of the body, but do not have any symptoms of this.

This study aims to find out:

1. Whether V940 plus pembrolizumab is better than placebo plus pembrolizumab at improving disease-free survival
2. Information about the side effects of these treatment in kidney cancer patients.

The study is open in Cambridge, Edinburgh, Glasgow, Manchester and London.

For more information and site contact details, please visit our clinical trials database on our website:
[php_everywhere instance="3"]